tiprankstipranks
Trending News
More News >
Avita Medical Ltd (RCEL)
:RCEL
US Market
Advertisement

Avita Medical (RCEL) Earnings Dates, Call Summary & Reports

Compare
410 Followers

Earnings Data

Report Date
Feb 19, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.31
Last Year’s EPS
-0.44
Same Quarter Last Year
Moderate Buy
Based on 5 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call highlighted significant progress in reimbursement issues and cost management, alongside strategic expansions in Europe. However, these positive developments were offset by notable revenue declines, reduced revenue guidance, and financial adjustments indicating ongoing challenges. Despite improvements in operational efficiency and cash management, the financial outlook remains cautious.
Company Guidance
In the third quarter of 2025, AVITA Medical reported approximately $17 million in revenue, which fell below expectations due to ongoing reimbursement disruptions. The company adjusted its full-year revenue guidance to a range of $70 million to $74 million, down from the previous $76 million to $81 million. Despite these challenges, AVITA has seen progress as all seven Medicare Administrative Contractors (MACs) have now confirmed reimbursement rates for RECELL procedures, fostering renewed demand and expected normalization of utilization in the coming quarters. The company is focusing on rebuilding order momentum, driving consistent product utilization, and enhancing forecast accuracy. AVITA also aims to capitalize on a $1.3 billion targeted opportunity within the broader U.S. market by concentrating on about 200 burn centers and trauma hospitals. Financially, the company reported a gross margin of 81.3% for the quarter and reduced operating expenses by 24% year-over-year, leading to a net loss improvement of 19% from the prior year. Looking ahead, AVITA plans to provide updated guidance for 2026 in early Q1, while maintaining cost discipline and balancing sheet flexibility to support its growth initiatives.
Reimbursement Progress for RECELL
Significant progress in reimbursement for RECELL procedures, with all 7 MACs now publishing or confirming acceptance of provider reimbursement rates, leading to renewed demand and expected utilization normalization.
European Expansion
RECELL GO received CE Mark approval in Europe, with the first patient treated in Germany, broadening access and underscoring global relevance.
Cost Management and Reduction
Operating expenses were reduced by 24% year-over-year, with a $7.2 million decrease, reflecting effective cost management and commercial restructuring.
Strong Gross Margin for RECELL
Gross profit margin for the RECELL franchise remained strong at 83.6%, contributing to overall financial health.
Cash Management Improvement
Significant improvement in cash management, with operating cash use reduced by nearly 40% quarter-over-quarter.

Avita Medical (RCEL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

RCEL Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Feb 19, 2026
2025 (Q4)
-0.31 / -
-0.44
Nov 06, 2025
2025 (Q3)
-0.33 / -0.46
-0.6225.81% (+0.16)
Aug 07, 2025
2025 (Q2)
-0.25 / -0.38
-0.636.67% (+0.22)
May 08, 2025
2025 (Q1)
-0.32 / -0.53
-0.7327.40% (+0.20)
Feb 13, 2025
2024 (Q4)
-0.45 / -0.44
-0.28-57.14% (-0.16)
Nov 07, 2024
2024 (Q3)
-0.45 / -0.62
-0.34-82.35% (-0.28)
Aug 08, 2024
2024 (Q2)
-0.50 / -0.60
-0.41-46.34% (-0.19)
May 13, 2024
2024 (Q1)
-0.48 / -0.73
-0.37-97.30% (-0.36)
Feb 22, 2024
2023 (Q4)
-0.39 / -0.28
-0.21-33.33% (-0.07)
Nov 09, 2023
2023 (Q3)
-0.43 / -0.34
-0.22-54.55% (-0.12)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

RCEL Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 06, 2025
$3.40
Aug 07, 2025
$5.38$4.25-21.00%
May 08, 2025
$9.33$6.97-25.29%
Feb 13, 2025
$8.78$10.57+20.39%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Avita Medical Ltd (RCEL) report earnings?
Avita Medical Ltd (RCEL) is schdueled to report earning on Feb 19, 2026, Before Open (Confirmed).
    What is Avita Medical Ltd (RCEL) earnings time?
    Avita Medical Ltd (RCEL) earnings time is at Feb 19, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is RCEL EPS forecast?
          RCEL EPS forecast for the fiscal quarter 2025 (Q4) is -0.31.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis